OBI announces the termination of license agreement with Odeon for the rights of OBI-999 and OBI-833 in China, Hong Kong and Macau

1.Date of termination of the contract or commitment:2024/05/10 2.Content of the contract or commitment: On 2022/2/22, OBI Pharma entered into a license agreement with Odeon Therapeutics (Hong Kong) Limited (hereinafter referred to as “ Odeon HK”) for the exclusive rights of OBI-999 and OBI-833 in China, Hong Kong and Macau, including the first right of […]